Excess Mortality Associated With Hypopituitarism in Adults: A Meta-Analysis of Observational Studies
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
Context: Several previous observational studies showed an association between hypopituitarism and excess mortality. Reports on reduction of standard mortality ratio (SMR) with GH replacement have been published recently. Objective: This meta-analysis assessed studies reporting SMR to clarify mortality risk in hypopituitary adults and also the potential benefit conferred by GH replacement. Data Sources: A literature search was performed in Medline, Embase, and Cochrane library up to March 31, 2014. Eligibility Criteria: Studies with or without GH replacement reporting SMR with 95% confidence intervals (95% CI) were included. Data Extraction and Analysis: Patient characteristics, SMR data, and treatment outcomes were independently assessed by two authors, and with consensus from third author, studies were selected for analysis. Meta-analysis was performed in all studies together, and those without and with GH replacement separately, using the statistical package metafor in R. Results: Six studies reporting a total of 19 153 hypopituiatary adults with a follow-up duration of more than 99 000 person years were analyzed. Hypopituitarism was associated with an overall excess mortality (weighted SMR, 1.99; 95% CI, 1.21–2.76) in adults. Female hypopituitary adults showed higher SMR compared with males (2.53 vs 1.71). Onset of hypopituitarism at a younger age was associated with higher SMR. GH replacement improved the mortality risk in hypopituitary adults that is comparable to the background population (SMR with GH replacement, 1.15; 95% CI, 1.05–1.24 vs SMR without GH, 2.40; 95% CI, 1.46–3.34). GH replacement conferred lower mortality benefit in hypopituitary women compared with men (SMR, 1.57; 95% CI, 1.38–1.77 vs 0.95; 95% CI, 0.85–1.06). Limitations: There was a potential selection bias of benefit of GH replacement from a post-marketing data necessitating further evidence from long-term randomized controlled trials. Conclusions: Hypopituitarism may increase premature mortality in adults. Mortality benefit from GH replacement in hypopituitarism is less pronounced in women than men.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Left untreated, anterior pituitary deficiencies are associated with decreased health and quality of life [55-59].”
From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [59]
In the citing paper
“undiagnosed and untreated deficiencies confer increased morbidity and mortality, which can be reversed by appropriate hormone replacement.”
From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [59]
In the citing paper
“However, GH replacement may reduce excess mortality from an SMR of 2.40 (95% CI 1.46-3.34) to 1.99 (95% CI 1.21-2.76),especially in men (60).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [60]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464 · cited 1×
“Quality assessment of the included articles was performed using the Newcastle Ottawa Scale (NOS) for cohort studies (17), modified for this meta-analysis.”
Method(2014) · Medical Entomology and Zoology · Cited by 17,633
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402 · cited 1×
“The increased risk of premature mortality associated with hypopituitarism was first identified by Rosén and Bengtsson (5) more than two decades ago.”
BackgroundThe prevalence of pituitary adenomas: A systematic review
Ezzat, S., Asa, S. L., Couldwell, W. T., Barr, C. E., Dodge, W. E., Vance, M. L., & McCutcheon, I. E. (2004) · Cancer · doi:10.1002/cncr.20412 · Cited by 1,345
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326 · cited 1×
“3 Median: 53 M; 51F N/A 56 (31) 119 (69) Bülow et al, 1997 (7) 344 62.”
Association between premature mortality and hypopituitarism
Tomlinson, J., Holden, N., Hills, R., Wheatley, K., Clayton, R., Bates, A., Sheppard, M., & Stewart, P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04006-x · Cited by 1,006
Self-citationBENEFICIAL EFFECTS OF GROWTH HORMONE TREATMENT IN GH-DEFICIENT ADULTS
Jørgensen, J. O. L., Thuesen, L., Ingemann-Hansen, T., Pedersen, S. A., Jørgensen, I., Skakkebaek, N. E., & Christiansen, J. S. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92328-3 · Cited by 890
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Cited by
Items 101–138 of 138
The Pituitary Gland - An Overview of Pathophysiology and Current Management Techniques
Ahmad, M. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1001527 · Cited by 1
Raizada, N., & Madhu, S. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_239_24 · Cited by 1
“[30] Available literature suggests that patients with SS are predisposed to coronary artery disease.”
BackgroundComputed Tomography Cardiac Angiography Findings in Patients With Sheehan Syndrome
Mohammad, A., Jehangir, M., Mir, S. A., Fatima, S. A., Baba, M. S., Laway, B. A., Bhat, J. A., & Shafi, N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.04.006 · Cited by 1
Biological poisons targeting the pituitary gland: insights across the five kingdoms
Sanchis-Pascual, D., Gómez, R. C., Morillas-Amat, P., Lara-Gálvez, D., Pérez-Cervantes, V., Masdeu-López-Cerón, P., & Merino-Torres, J. F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1708792 · Cited by 1
The Impact of Growth Hormone Deficiency on Endothelial Function in Childhood Brain Cancer Survivors
Crocco, M., Malerba, F., Zampatti, N., Nosratian, V., Bigatti, C., Panciroli, M., Casirati, A., Calevo, M. G., Maghnie, M., & Iorgi, N. D. (2025) · Cancers · doi:10.3390/cancers17233746 · Cited by 1
“The higher prevalence of pituitary deficits and neuromotor involvement in CBCS may explain some differences observed between CBCS and other cancer types [48].”
Potential impacts of adult growth hormone deficiency: a population-based study in England
Criseno, S., Gayton, E. L., Araghi, M., Machtiger-Azoulay, N., & Toogood, A. A. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-108782 · Cited by 1
Medical Management for Pituitary Adenoma Patients
Hong, G. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-56691-7_21 · Cited by 1
Impact of Repetitive and Traumatic Brain Injury on Pituitary Function
Ioachimescu, A. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_24 · Cited by 1
Acromegaly: Overview and Current Management Options
Ahmad, M., & Weil, R. J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002814 · Cited by 1
Endocrine Issues in Neurocritical Care
Long, M. T., Leiendecker, E., Dollerschell, J. T., Tokarcyzk, A., & Coursin, D. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-62220-5_35 · Cited by 1
Hypothalamic-Pituitary Axis Involvement in Primary Central Nervous System Lymphoma
Ganga, C. S. L., Navas-Moreno, V., Sebastián‐Valles, F., Cannata‐Ortiz, J., & Marazuela, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf620 · Cited by 1
Adult Growth Hormone Deficiency : A Practical Approach to Diagnosis and Treatment for Neurosurgeons
Nishioka, H., & Shimatsu, A. (2022) · Japanese Journal of Neurosurgery · doi:10.7887/jcns.31.313 · Cited by 1
Challenging Questions in the Management of Acromegaly in the Young
Youssef, N., & Yuen, K. C. J. (2022) · Contemporary Endocrinology · doi:10.1007/978-3-031-16258-9_15 · Cited by 1
Hypopituitarism, Causes, Diagnosis, Management and Mortality
Fountas, A., & Karavitaki, N. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64277-0 · Cited by 1
Giving mouth-to-mouth ventilations? This pocket mask could protect you from H.I.V. infection.
Juip, M., & Harned, J. C. (1988) · PubMed · Cited by 1
Biscotto, I. P. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-11062021-134324
ACTUAL ASPECTS OF PITUITARY ADENOMAS AND ISSUES OF EPIDEMIOLOGY STUDYING
Nazaralieva, E. T., Cherebillo, V. Y., & Khachatryan, V. A. (2021) · Современные проблемы науки и образования · doi:10.17513/spno.31051
Diagnosis and Treatment of Adult Growth Hormone Deficiency
Kim, J. H. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.5.400
Adult Growth Hormone Deficiency
Jørgensen, J. O. L. (2022) · doi:10.1093/med/9780198870197.003.0022
Donegan, D. M., & Bancos, I. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190862923.003.0035
Yuen, K. C. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-99918-6_19
Hypothalamo-pituitary Disorders in Childhood and Adolescence
Cerbone, M., Dattani, M., Maghnie, M., & Patti, G. (2023) · Endocrinology · doi:10.1007/978-3-030-18901-3_2-1 · Cited by 1
Hypopituitarism in Adults: Rational Approaches to Diagnosis and Treatment
Almalki, M. (2023) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0043-1768587
Hu, Y., Yuan, C., Abdulnaimu, M., Memetmin, J., Jie, Z., Tuhuti, A., Abudueini, H., & Guo, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1290007 · Cited by 1
“A meta-analysis has reported a 2-fold increase in all-cause mortality among patients with functional GH cell adenomas (14).”
BackgroundLost Connection: A Case Report of Interrupted Pituitary Stalk Syndrome
Idrees, R. B., Malik, M., Cheema, F. E., Khalid, M., Malik, F., & Chaudhary, M. H. (2024) · Cureus · doi:10.7759/cureus.60232
Hypothalamo-Pituitary Disorders in Childhood and Adolescence
Cerbone, M., Dattani, M., Maghnie, M., & Patti, G. (2024) · Endocrinology · doi:10.1007/978-3-030-23709-7_2 · Cited by 1
Li, M., Mo, C., Yan, S., Zhao, R., Luo, W., Yang, L., Wang, H., & Hu, J. (2024) · PeerJ · doi:10.7717/peerj.18536 · Cited by 1
Hypopituarism - Not such an obvious symptom
Grzybek, M., Wilczyńska, B., Kasprzak, A., Kułaga, M., Mazur-Lesińska, D., Szostak, B., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., & Kasprzak, M. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.81.59372
Gruber, L. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197628638.003.0035
Alterations of lipoprotein subfractions in GH-deficient adults
Ratku, B., Lőrincz, H., Csiha, S., Bíró, L., Erdei, A., Berta, E., Ujvárosy, D., Bodor, M., Nagy, E. V., Szabó, Z., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696426
“Since literature data suggest that excess mortality in AGHD is mainly due to cardiovascular and cerebrovascular disorders (4, 5), dyslipidemia, with its well-established causal role in these diseases (6), is speculated to be the strongest contributor to the increased mortality (7, 8).”
Secondary Hypogonadism and Effects of Testosterone Replacement Therapy on Cardiovascular Events
Munro, V., Law, J., Matheson, K. J., & Imran, S. A. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf631 · Cited by 2
Taguchi, T., Kimura, K., Tsuji, S., Ito, S., Takamura, S., Shimotatara, H., Shimizu, N., Kubo, H., Hoshiyama, A., Hayashi, A., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf193 · Cited by 1
“Moreover, although AGHD is linked to a higher prevalence of cardiovascular diseases and increased mortality risk, GHRT can reduce the mortality risk [8].”
Hypopituitarism, causes, diagnosis, management and mortality
Fountas, A., Effraimidis, G., & Karavitaki, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00308-3 · Cited by 1
Das, L., Sahoo, J., Laway, B. A., Bansiwal, S. K., Singh, P., Korbonits, M., Rao, S. D., Bhadada, S. K., & Dutta, P. R. (2025) · Clinical Endocrinology · doi:10.1111/cen.70075
“Regarding the use of bone ‐ active agents, anti ‐ resorptive therapy in the form of annual zoledronic acid was used in 23 patients (21.9%), with a median dose of 3 [2 – 4].”
InfluentialYu, K., & Bancos, I. (2026) · Pituitary · doi:10.1007/s11102-026-01652-2
“Meta-analyses of patients with hypopituitarism, including SAI, reported excess mortality, with women demonstrating higher relative risk than men [79, 80].”
Iglesias, P. (2026) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2026.2649164 · Cited by 1
“For example, growth hormone (GH) deficiency (GHD) in adults and hypopituitarism are associated with excess mortality, predominantly from CV causes, and a high prevalence of metabolic syndrome and CV events, even under replacement therapy [4–7].”
Abe, I., Kubo, K., Fujita, Y., Ochi, K., Wada, T., Mitsuoka, R., Takeshita, K., Higashi, A., Kato, T., Kudo, T., et al. (2026) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2026.01003
Krylov, V. V., Usachev, D. Y., Grigoriev, A. Y., Cherebillo, V. Y., Kalinin, P. L., Kutin, M. A., Pashaev, B., Rudenko, P. G., Gormolysova, E., Dedov, I. I., et al. (2026) · Endocrine Surgery · doi:10.14341/serg13053 · Cited by 1
Metadata
- Authors
- Pappachan, J. M., Raskauskiene, D., Kutty, V. R., & Clayton, R. N.
- Affiliations
- Walsall Manor Hospital (GB)
- Sree Chitra Thirunal Institute for Medical Sciences and Technology (IN)
- University Hospitals of North Midlands NHS Trust (GB)
- Corresponding author
- Pappachan, Joseph M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-04-01
- Volume
- 100
- Issue
- 4
- Pages
- 1405-1411
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2097556482
- Semantic Scholar
- 00593eb004f6fde4fa72eed78a1247a323891575
- Cited by
- 138
- References
- 34
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 18 · 2023: 19 · 2022: 16 · 2021: 9 · 2020: 13 · 2019: 9 · 2018: 10 · 2017: 10 · 2016: 8 · 2015: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- excess mortality, standardized mortality ratio, growth hormone replacement therapy, premature mortality, sex differences, post-marketing surveillance
- MeSH terms
- Adult, Female, Humans, Hypopituitarism, Male, Middle Aged, Human Growth Hormone, Hormone Replacement Therapy, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.